Perspectives on the nanocarriers with miRNAs for targeting melanoma stemness through epigenetic regulation
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Several research reports delineated the significant role of miRNAs in cancer proliferation, and their modulatory role in cancer mitigation, and drug resistance. Melanoma cells have been acquiring stemness to several chemotherapeutic agents through drug efflux proteins, epigenetic modulation, and DNA repair. miRNAs could be applied as novel therapeutic modalities for treating several kinds of cancers to modulate these mechanisms involved in stemness. Nanocarriers to carry these tumor-targeting miRNAs to modulate stemness are a prominent strategy to overcome their low penetrability, minimal stability, and nonspecificity. We have searched several public databases such as PubMed, Medline, Google scholar, and NLM and obtained the information pertinent to the miRNA-based nanocarrier systems to target stemness through epigenetic modulation in melanomas. This review delineates that various miRNAs can modulate the stemness in melanomas by specific intricate epigenetic signaling, and other cell-based signaling mechanisms. Specific nanocarrier formulations with specific miRNAs are optimal methods to deliver these miRNAs in order to achieve significant entrapment efficiency, loading efficiency, and stability. Furthermore, the combinatorial regimen of FDA-approved chemotherapeutic molecules with tumor-targeting miRNAs and chemotherapy combined with nanocarriers can efficiently deliver the utmost therapeutic window by targeting tumor matrix, invasion, metastasis, and angiogenesis in melanomas. Substantial research should focus on the clinical application of this gene therapy in melanomas using these low immunogenic, highly degradable, and biocompatible combinatorial nanotherapeutic regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Pigment cell & melanoma research - 36(2023), 3-4 vom: 06. Mai, Seite 268-287 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Junqi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epigenetics |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 01.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/pcmr.13081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352017937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352017937 | ||
| 003 | DE-627 | ||
| 005 | 20231226052749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/pcmr.13081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352017937 | ||
| 035 | |a (NLM)36691113 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Junqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perspectives on the nanocarriers with miRNAs for targeting melanoma stemness through epigenetic regulation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 01.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Several research reports delineated the significant role of miRNAs in cancer proliferation, and their modulatory role in cancer mitigation, and drug resistance. Melanoma cells have been acquiring stemness to several chemotherapeutic agents through drug efflux proteins, epigenetic modulation, and DNA repair. miRNAs could be applied as novel therapeutic modalities for treating several kinds of cancers to modulate these mechanisms involved in stemness. Nanocarriers to carry these tumor-targeting miRNAs to modulate stemness are a prominent strategy to overcome their low penetrability, minimal stability, and nonspecificity. We have searched several public databases such as PubMed, Medline, Google scholar, and NLM and obtained the information pertinent to the miRNA-based nanocarrier systems to target stemness through epigenetic modulation in melanomas. This review delineates that various miRNAs can modulate the stemness in melanomas by specific intricate epigenetic signaling, and other cell-based signaling mechanisms. Specific nanocarrier formulations with specific miRNAs are optimal methods to deliver these miRNAs in order to achieve significant entrapment efficiency, loading efficiency, and stability. Furthermore, the combinatorial regimen of FDA-approved chemotherapeutic molecules with tumor-targeting miRNAs and chemotherapy combined with nanocarriers can efficiently deliver the utmost therapeutic window by targeting tumor matrix, invasion, metastasis, and angiogenesis in melanomas. Substantial research should focus on the clinical application of this gene therapy in melanomas using these low immunogenic, highly degradable, and biocompatible combinatorial nanotherapeutic regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a epigenetics | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a miRNAs | |
| 650 | 4 | |a nanodelivery | |
| 650 | 4 | |a signaling pathways | |
| 650 | 4 | |a stemness | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Zhang, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Beeraka, Narasimha M |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kuo |e verfasserin |4 aut | |
| 700 | 1 | |a Sinelnikov, Mikhail Y |e verfasserin |4 aut | |
| 700 | 1 | |a Manogaran, Prasath |e verfasserin |4 aut | |
| 700 | 1 | |a Bannimath, Gurupadayya |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolenko, Vladimir N |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Ruitai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pigment cell & melanoma research |d 2008 |g 36(2023), 3-4 vom: 06. Mai, Seite 268-287 |w (DE-627)NLM178364223 |x 1755-148X |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:3-4 |g day:06 |g month:05 |g pages:268-287 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/pcmr.13081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 3-4 |b 06 |c 05 |h 268-287 | ||